Prothena Q4 net loss narrows

Prothena

19/02/2026 21:20

Overview

Biotechnology firm's Q4 revenue fell significantly yr/yr

Net loss for Q4 increased compared to the previous year

Company expects 2026 net cash used in operations to decrease

Outlook

Prothena expects 2026 net cash used in operations to be $50 to $55 mln

Company anticipates ending 2026 with approximately $255 mln in cash

Result Drivers

REVENUE DECLINE - Q4 revenue decreased significantly due to lower collaboration revenue from Bristol Myers Squibb

R&D EXPENSES - Decrease in R&D expenses due to lower clinical trial, personnel, manufacturing, and consulting costs

RESTRUCTURING IMPACT - Net loss includes restructuring charges and valuation allowance against deferred tax assets

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$21.59 mln
Q4 Operating Expenses
$24.22 mln
Q4 Pretax Profit
-$21.58 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Prothena Corporation PLC is $18.50, about 103.5% above its February 18 closing price of $9.09

Press Release: ID:nBw5pV9mFa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)